A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
July 7, 2017
End Date
December 28, 2018
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
July 7, 2017
End Date
December 28, 2018